DeepHealth receives FDA clearance for remote scanning solution

LOS ANGELES - DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), a $4.07 billion medical imaging company, has received FDA 510(k) clearance for TechLive, a remote scanning solution that enables centralized operation of MR, CT, PET/CT, and Ultrasound procedures, the company announced Thursday. According to InvestingPro data, RadNet has shown strong revenue growth of nearly 13% over the last twelve months, though analysts currently consider the stock overvalued based on their Fair Value analysis.

The technology allows technologists to remotely operate imaging equipment at multiple locations simultaneously, addressing workforce shortages in the radiology sector. RadNet has already connected more than 300 imaging systems to the TechLive platform.

During a pilot deployment at 64 RadNet facilities in New York, the solution contributed to a 42% decrease in MRI room closure hours in the second quarter of 2025 compared to the same period in 2024, according to the company’s press release. This operational improvement comes as RadNet maintains a healthy current ratio of 2.01, indicating strong short-term financial stability. InvestingPro subscribers can access 7 additional key insights about RadNet’s financial health and growth prospects.

The system also enables experienced sonographers and physicians to remotely guide on-site technologists through complex ultrasound cases, which typically require real-time operator expertise.

"By enabling real-time remote expertise, we are not only addressing today’s staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities," said Sham Sokka, Chief Operating and Technology Officer at DeepHealth.

The vendor-agnostic solution comes at a time when radiology workloads have increased while qualified technologist numbers have not grown proportionally, creating operational challenges for imaging centers.

RadNet operates 401 outpatient imaging centers across eight states and employs over 11,000 people including contracted radiologists, full-time and per diem employees, and technologists. With the company’s next earnings report due in just 3 days, investors can access comprehensive analysis and Fair Value estimates through InvestingPro’s detailed research reports, available for over 1,400 US stocks including RadNet.

In other recent news, RadNet reported robust first-quarter earnings, with revenue reaching $471.4 million, surpassing the Street’s forecast of $443.1 million and Raymond James’s estimate of $450.7 million. The company’s adjusted EBITDA also exceeded expectations, coming in at $46.4 million, compared to the Street’s prediction of $45.5 million. Following these results, RadNet’s management has slightly increased the full-year guidance to a range of $283-293 million. Additionally, RadNet has secured a $100 million incremental term loan from Barclays Bank PLC, intended for acquisitions, with the loan maturing on April 18, 2031. In a strategic move, RadNet acquired See-Mode Technologies, integrating its AI applications for ultrasound imaging, which has shown up to a 30% reduction in scan time. Truist Securities has reiterated its Buy rating on RadNet, maintaining a price target of $74, while Raymond James increased its price target to $66 from $65, reflecting confidence in the company’s performance. RadNet has also entered into a new reimbursement agreement for its Enhanced Breast Cancer Detection program with several medical groups. These developments highlight RadNet’s ongoing efforts to expand its capabilities and enhance its service offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.